Deepc has closed a $13m Series A extension round, bringing the German company’s total funding to $30m.
The round was co-led by Sofinnova Partners and Bertelsmann Investments. New investors KHP Ventures and SwissHealth Ventures participated, along with existing investor Winning Mindset Ventures.
Deepc said the funding will be used to advance its deepcOS system. The company is eyeing international expansion, with a priority on penetrating the US market, further expanding in the UK, and doubling down in European regions.
The platform is currently used in hospitals in the UK, Switzerland, Germany, and Belgium.
Deepc’s software specialises in radiology access and data integration. It provides radiologists with a range of AI solutions to help with diagnoses and treatment decisions.
Deepc’s CEO Dr Franz Pfister said: "We believe that the potential for AI in healthcare will only be realised if we can bridge the gap between cutting-edge AI and clinical practice. Our platform makes it easy for organisations to adopt the best AI technologies at pace and scale, enabling faster, more accurate diagnoses and ultimately improving patient outcomes.
In February 2024, deepc acquired the Osimis Platform, a medical imaging software solution. At the time, the company said it was a “strategic move” to consolidate market share.
Radiology has been one of AI’s biggest use cases in healthcare as the technology advances. A 2023 report by GlobalData predicts that global revenue for AI platforms across healthcare will reach $18.8bn by 2027, with radiology being one of the key growth factors.
While AI’s ability to enhance workflows is clear, some in the industry have warned that its long-term implementation could be hindered without a robust digital infrastructure.
The deepc funding represents the latest investment by Sofinnova’s digital medicine fund, which set aside $200m for emerging companies in the space in October 2023.
Also on the life sciences venture capital company’s books is Betteromics, which gained $20m late last year for its AI cloud platform. BioCorteX, Kiro, and Cure 51 are also in the portfolio, among others.
